Literature DB >> 16205470

Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia.

Gérard M London1, Sylvain J Marchais, Alain P Guérin, Fabien Métivier.   

Abstract

PURPOSE OF REVIEW: Arterial calcification in chronic kidney disease (CKD) is associated with increased cardiovascular risk. The mechanisms responsible for arterial calcification include alterations of mineral metabolism and expression of mineral-regulating proteins. RECENT
FINDINGS: Arterial calcification is similar to bone formation, involving differentiation of vascular smooth muscle cells (VSMCs) into phenotypically distinct osteoblast-like cells. Elevated phosphate and/or calcium trigger a concentration-dependent increase of calcium precipitates in VSMC in vitro. The calcification is initiated by VSMC release of membrane-bound matrix vesicles and formation of apoptotic bodies. The presence of serum prevents these changes, indicating the presence of calcification inhibitors. Arterial calcification occurs in two sites: the tunica intima and tunica media. Intimal calcification is a marker of atherosclerotic disease and is associated with arterial stenotic lesions. Medial calcification influences outcome by promoting arterial stiffening whose principal consequences are left-ventricular hypertrophy and altered coronary perfusion. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in CKD patients. Age, duration of dialysis, smoking and diabetes are risk factors for the development of arterial calcification in end-stage renal disease. Oversuppression of parathyroid hormone and low bone turnover potentiate the development of arterial calcification.
SUMMARY: Arterial disease in CKD patients is characterized by extensive calcification. Evidence has accumulated pointing to the active and regulated nature of the calcification process. Elevated phosphate and calcium may stimulate sodium-dependent phosphate cotransport involving osteoblast-like changes in cellular gene expression. Arterial calcification is responsible for stiffening of the arteries with increased left-ventricular afterload and abnormal coronary perfusion as the principal clinical consequences.

Entities:  

Mesh:

Year:  2005        PMID: 16205470     DOI: 10.1097/01.mnh.0000168336.67499.c0

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  66 in total

Review 1.  Negative trials in nephrology: what can we learn?

Authors:  James E Novak; Jula K Inrig; Uptal D Patel; Robert M Califf; Lynda A Szczech
Journal:  Kidney Int       Date:  2008-06-18       Impact factor: 10.612

2.  Calcification of the aortic arch predicts cardiovascular and all-cause mortality in chronic hemodialysis patients.

Authors:  Chien-Te Lee; Chiang-Chi Huang; Chung-Yao Hsu; Terry Ting-Yu Chiou; Hwee-Yeong Ng; Chien-Hsing Wu; Wei-Hung Kuo; Yueh-Ting Lee
Journal:  Cardiorenal Med       Date:  2014-03-01       Impact factor: 2.041

3.  Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease.

Authors:  Jinnie J Rhee; Jialin Han; Maria E Montez-Rath; Sun H Kim; Mark R Cullen; Randall S Stafford; Wolfgang C Winkelmayer; Glenn M Chertow
Journal:  J Diabetes Complications       Date:  2019-09-03       Impact factor: 2.852

Review 4.  FGF23: its role in renal bone disease.

Authors:  Masafumi Fukagawa; Junichiro James Kazama
Journal:  Pediatr Nephrol       Date:  2006-08-24       Impact factor: 3.714

5.  Osteopontin protects against high phosphate-induced nephrocalcinosis and vascular calcification.

Authors:  Neil J Paloian; Elizabeth M Leaf; Cecilia M Giachelli
Journal:  Kidney Int       Date:  2016-03-09       Impact factor: 10.612

Review 6.  Technical approach to iliac crest biopsy.

Authors:  Joel D Hernandez; Katherine Wesseling; Renata Pereira; Barbara Gales; Rick Harrison; Isidro B Salusky
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

7.  Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease.

Authors:  Madeleine V Pahl; Nosratola D Vaziri; Jun Yuan; Sharon G Adler
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

8.  Vascular calcification and atherosclerosis in hemodialysis patients: what can we learn from the routine clinical practice?

Authors:  Saso Gelev; Goce Spasovski; Sonja Dzikova; Zoran Trajkovski; Goge Damjanovski; Vili Amitov; Aleksandar Sikole
Journal:  Int Urol Nephrol       Date:  2008-06-27       Impact factor: 2.370

9.  Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure.

Authors:  Ely M Sebastian; Larry J Suva; Peter A Friedman
Journal:  Bone       Date:  2008-08-09       Impact factor: 4.398

Review 10.  Cardiovascular risk and management in chronic kidney disease.

Authors:  Diana Rucker; Marcello Tonelli
Journal:  Nat Rev Nephrol       Date:  2009-05       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.